F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comIndraprastha Medical Corporation Ltd (IMCL), a leading healthcare service provider, is known for operating the renowned Indraprastha Apollo Hospitals in New Delhi. With over three decades of experience, IMCL offers top-tier medical services in cardiology, oncology, neurology, and more. As India’s demand for quality healthcare continues to rise, IMCL is strategically positioned to benefit from long-term sectoral growth.
In this blog, we’ll explore the share price target of Indraprastha Medical Corporation Ltd from 2025 to 2030, along with key investment insights based on its current financials and market performance.
| Detail | Value |
|---|---|
| Current Price | ₹458.95 |
| Previous Close | ₹444.70 |
| Day's High | ₹488.25 |
| Day's Low | ₹458.00 |
| 52-Week High | ₹572.00 |
| 52-Week Low | ₹307.25 |
| Market Capitalization | ₹4,271 Cr |
| VWAP (Volume Weighted Avg) | ₹476.73 |
| Beta (Volatility) | 1.51 |
| Book Value per Share | ₹57.21 |
| Dividend Yield | 0.97% |
| Face Value | ₹10 |
Indraprastha Medical Corporation Ltd is a part of the Apollo Hospitals Group and manages the flagship Indraprastha Apollo Hospital in Delhi. With over 700 beds and advanced medical technology, it is one of the most trusted healthcare institutions in India.
Operates one of India’s largest super-specialty hospitals.
Benefits from growing demand in medical tourism.
High operational efficiency and patient footfall.
Collaborations with international insurance providers and health networks.
Leadership in robotic surgery and advanced diagnostics.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 51.00% |
| Retail & Others | 42.72% |
| Foreign Institutions | 2.72% |
| Mutual Funds | 2.62% |
| Other Domestic Institutions | 0.94% |
The shareholding structure reveals strong promoter backing and a healthy level of retail investor confidence.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 460 | 500 |
| 2026 | 510 | 550 |
| 2027 | 560 | 610 |
| 2028 | 620 | 680 |
| 2029 | 690 | 750 |
| 2030 | 770 | 850 |
These projections are based on technical analysis, healthcare sector trends, and the company’s historical growth trajectory.
By the end of 2025, the stock is likely to trade steadily in the ₹460–₹500 range, supported by strong Q1 and Q2 performance.
Why?
High patient inflow post-COVID due to rising health awareness
Solid earnings due to expansion in diagnostics and emergency care
Improved profit margins through cost optimization
Investment Advice: Consider accumulating on dips. Healthcare sector is showing stable defensive characteristics.
The stock may see moderate appreciation by 2026 due to digital healthcare integration.
Why?
Growth in telemedicine services
AI-driven diagnostics for better patient outcomes
Margins expected to improve with increased automation
Investment Advice: Hold and increase exposure through SIPs for long-term returns.
With expanding services and newer technologies, the company is likely to attract institutional interest.
Why?
Collaborations with international healthcare providers
More robotic surgery units installed
Foreign medical tourists contributing to revenue
Investment Advice: Great time to reinvest dividends or make additional lump-sum investments.
The healthcare sector is expected to grow exponentially and IMCL is expected to capitalize on that.
Why?
More Tier-2 city patient inflow
Expansion of specialized units like oncology and cardiology
Consistent growth in topline revenue
Investment Advice: Keep holding. Consider profit booking above ₹650 if portfolio allocation increases.
Increased infrastructure and healthcare budget by the government may positively impact the stock.
Why?
Healthcare incentives under national health missions
Better insurance integration and claims management
Increasing demand for elderly care services
Investment Advice: Long-term investors should hold. Short-term traders can exit partially.
By 2030, the company may become a leader in digital healthcare solutions and robotic surgeries.
Why?
High patient trust and brand value
Integrated healthcare apps and AI-driven OPD
Entry into home healthcare and wearable diagnostics
Investment Advice: Strong long-term buy for those targeting compounding growth and portfolio stability.
Yes, if you're looking for stable, long-term growth in the defensive healthcare sector.
Growing demand for healthcare and diagnostics
Technological advancements improving efficiency
Low debt and consistent profit growth
Steady dividend payouts
Regulatory pressure on healthcare pricing
High dependency on single-location hospital
Doctor shortages or staff attrition
Competitive pressure from other hospital chains
Advice: Keep track of quarterly results and monitor stock performance around earnings calls (especially Q3 and Q4).
Indraprastha Medical Corporation Ltd is a strong healthcare play with a consistent growth pattern and solid fundamentals. With rising healthcare demand, especially post-pandemic, the company is expected to benefit from both domestic and international patient inflow.
Currently trading at around ₹458.95, the share price could reach a range of ₹850 by 2030 if it continues to deliver robust performance. Long-term investors seeking stability and sector exposure may consider IMCL as a part of their core portfolio.
1. What is the current share price of Indraprastha Medical?
As of August 2025, it is trading around ₹458.95.
2. Is Indraprastha Medical a good long-term investment?
Yes, due to strong fundamentals, sector growth, and reliable management.
3. What is the 52-week high of IMCL?
₹572.00 is the 52-week high.
4. What is the dividend yield of Indraprastha Medical?
The company offers a dividend yield of 0.97%.
5. What is the face value of the stock?
The face value is ₹10.
6. Who are the major shareholders in IMCL?
Promoters hold 51%, while retail investors hold around 42.72%.
7. What are the growth catalysts for this stock?
Rising healthcare demand, medical tourism, and digital health services.
8. Is the stock volatile?
With a beta of 1.51, it shows moderate volatility.
9. Should I invest in IMCL now?
Yes, especially if you’re looking for healthcare sector exposure and long-term capital appreciation.
10. What is the long-term target of Indraprastha Medical stock?
By 2030, the stock may touch between ₹770 and ₹850 if current trends continue.
Disclaimer: This blog is for informational purposes only and should not be considered financial advice. Please consult a SEBI-registered advisor before making any investment decisions.
Register & Login